| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3837 |
| Trial ID | NCT06349343 |
| Disease | Systemic Lupus Erythematosus |
| Altered gene | CD19|BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | BCMA/CD19 Hi-TCR-T cells |
| HLA | HLA-independent |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | Clinical Study of the Safety and Efficacy of CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus |
| Year | 2024 |
| Country | China |
| Company sponsor | Wuhan Union Hospital, China |
| Other ID(s) | UHCT230949 |
| Cohort 1 | |||||||||
|
|||||||||